rifampicin + levofloxacin + ciprofloxacin

Rifampicin + levofloxacin + ciprofloxacin is an antibiotic combination regimen used for the medico-surgical treatment of staphylococcal osteoarticular infections (OAIs), including prosthetic joint infections and chronic osteomyelitis. This regimen was the subject of the Ciné-RIF study, a prospective pharmacokinetic trial sponsored by Groupe Hospitalier Diaconesses Croix Saint-Simon. Rifampicin serves as the primary bactericidal agent, targeting bacterial DNA-dependent RNA polymerase to inhibit RNA synthesis, and is valued for its ability to penetrate bone tissue and bacterial biofilms. Levofloxacin and ciprofloxacin are fluoroquinolone antibiotics that inhibit bacterial DNA gyrase and topoisomerase IV; they are used as companion agents to enhance efficacy and prevent the emergence of rifampicin resistance. The components are typically administered orally as separate generic or branded medications.

Other names

rifampin + levofloxacin + ciprofloxacin